Renovorx initiates patient enrollment at university of texas southwestern medical center for pivotal phase iii tiger-pac clinical trial

Los altos, calif. & dallas--(business wire)--renovorx, inc. (“renovorx” or the “company”) (nasdaq: rnxt), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced that the university of texas (ut) southwestern medical center is now enrolling pancreatic cancer patients in the open label, randomized phase iii tiger-pac clinical trial. the study is investigating renovogem which utilizes renovorx's proprietary therapy platform, tamp™, to provide improved.
RNXT Ratings Summary
RNXT Quant Ranking